Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | TBXAS1 | P24557 | 7/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5405354 | 0.92 | TSHR (0.47) | KMT2AALDH1A1TSHRLMNAMEN1 | |
| SCHEMBL5416779 | 0.91 | TBXAS1 (0.44) | KCNA5KMT2ATBXAS1HTT | |
| SCHEMBL5403047 | 0.86 | KCNA5 (0.46) | KCNA5KMT2APKMALDH1A1MAPT | |
| SCHEMBL5401121 | 0.85 | MEN1 (0.41) | KMT2AALDH1A1MAPTTSHRLMNA | |
| SCHEMBL5402349 | 0.85 | KCNA5 (0.50) | KCNA5KMT2APKMALDH1A1MAPT | |
| SCHEMBL5409427 | 0.85 | ALDH1A1 (0.53) | KCNA5KMT2APKMALDH1A1MAPT | |
| SCHEMBL5403476 | 0.85 | FFAR1 (0.41) | KMT2AALDH1A1TSHRLMNAHTT | |
| SCHEMBL5418597 | 0.84 | TRPV1 (0.47) | KCNA5KMT2APKMALDH1A1MAPT | |
| SCHEMBL5409818 | 0.84 | FFAR1 (0.45) | KMT2AALDH1A1TSHRLMNAMEN1 | |
| SCHEMBL5392909 | 0.84 | TSHR (0.51) | KCNA5KMT2APKMALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7285680-B2 | β-alanine derivatives and the use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-10-23 | — | — | US | disclosed |
| US-20050256160-A1 | Beta-alanine derivatives and the use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-11-17 | — | — | US | disclosed |
| EP-1533294-A1 | BETA-ALANINE DERIVATIVE AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-05-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256160-A1 | Beta-alanine derivatives and the use thereof | TGFB1, PML, APOB | KCNA5 3586/4885KMT2A 2451/4885PKM 880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.